Loading data for CVM — first visit, this takes a few seconds.
CEL-SCI Corporation (CVM)
NYSE American: CVM
· 实时价格 · USD
1.52
-0.02 (-1.30%)
收盘价： Sep 10, 2026, 3:59 PM
股价、关键数字和最新消息，都在这一页。
CEL-SCI Corporation（CVM）股价、分析与数据
-0.97% (1D)
| 买价 | 1.53 |
| 市值 | 25.9M |
| 营收（TTM） | n/a |
| 净利润（TTM） | -22.7M |
| 0.62 | |
| -1.69 | |
| n/a | |
| -0.23 | |
| 市净率（TTM） | 2.37 |
| 市销率（TTM） | 0.00 |
| 财报日期 | Feb 12, 2026 |
| 卖价 | 1.55 |
| 成交量 | 51,332 |
| 20日均量 | 309,314 |
| 开盘价 | 1.57 |
| 前收盘价 | 1.54 |
| 日内区间 | 1.52 - 1.58 |
| 52周区间 | 0.89 - 10.83 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | Aug 28, 1996 |
关于 CVM
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulat...
公司完整简介财报意外
CEL-SCI 已于 Jan 13, 2025 发布季度财报：
- 营收为 $0 低于预期 $0, ， NaN% 同比增长.
- 每股收益为 -2.7 超出预期 0.60, ， 43.75% 同比增长.
